Clinical Takeaway
In this rigorous crossover trial, neither a low nor a high single dose of CBD directly altered cortical excitability or produced measurable sedation in healthy adults. This suggests that CBD’s well-documented anti-seizure benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome may depend heavily on its interaction with co-administered medications such as clobazam rather than on a standalone effect on brain excitability. Patients and clinicians should understand that CBD’s effectiveness in epilepsy treatment is likely context-dependent and not simply a result of CBD acting alone on seizure thresholds.
#12 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
What This Study Teaches Us
In healthy volunteers, CBD at doses up to 700 mg did not reduce cortical excitability on objective neurophysiologic testing and showed no sedative effects. This suggests CBD’s seizure-reducing benefits in approved indications may depend on interactions with other medications rather than direct effects on brain excitability.
Why This Matters Clinically
Clinicians prescribing CBD for seizures have relied on assumptions about its direct anti-epileptic mechanism. If CBD works primarily through drug interactions (particularly with clobazam), it changes how we think about dosing, drug selection, and efficacy in patients on different medication regimens. Patients also deserve clarity about whether they’re getting direct brain effects or indirect ones.
Study Snapshot
| Study Design | Randomized, double-blind, placebo-controlled 3-way crossover trial |
| Population | 25 healthy males |
| Intervention | Single oral doses of 30 mg CBD, 700 mg CBD, or placebo on separate visits |
| Primary Outcome | Effects on cortical excitability measured by transcranial magnetic stimulation (TMS) combined with electromyography and electroencephalography |
| Key Result | CBD showed no significant effects on single or paired pulse TMS-EMG parameters; minimal EEG signal clusters at specific timepoints; no sedative effects on validated CNS testing |
Where This Paper Deserves Skepticism
This is a healthy volunteer study, not a patient with epilepsy, so results may not predict efficacy in diseased brain states where seizure threshold and cortical function differ substantially. The abstract provides no detail on funding source, statistical power calculation, or multiple comparison correction, raising questions about false positive risk in the EEG clusters reported. Twenty-five subjects is modest for detecting small but clinically meaningful effects, and the study tested only acute single-dose pharmacology, not chronic effects.
Dr. Caplan’s Take
I find this study sobering and important. It challenges a comfortable assumption that CBD works through direct suppression of brain excitability. The fact that it shows minimal cortical effects in healthy people strongly suggests the approved seizure indications rely on pharmacokinetic interactions, most notably with clobazam. That doesn’t make CBD ineffective, but it narrows the biological story considerably and raises questions about its use outside those specific drug combinations. I’ll be paying attention to follow-up work in actual patient populations and with concomitant medications.
Clinical Bottom Line
CBD does not appear to directly suppress cortical excitability or produce sedation in healthy volunteers. Its clinical benefit in approved seizure disorders likely depends on interactions with co-prescribed medications rather than intrinsic anti-epileptic properties.
| |
Have thoughts on this? Share it:
